In 2025, China's innovative drug industry reached a record high in two key data points. Concept stocks with high growth potential have been revealed.

The State Drug Administration announced on January 3 that by 2025, China's development of innovative drugs has reached a new level: a total of 76 innovative drugs were approved for market launch throughout the year, a significant increase from the 48 in 2024; at the same time, the total amount of out-licensed transactions for innovative drugs exceeded 130 billion US dollars, with over 150 transactions, both of which reached historical highs. In terms of categories, among the 76 innovative drugs approved in 2025, 47 are chemical drugs, 23 are biological products, and 6 are traditional Chinese medicine. Among them, domestic innovative drugs performed outstandingly: Chinese-produced chemical drugs accounted for 38, Chinese-produced biological products accounted for 21, with proportions of 80.85% and 91.30% respectively. In terms of future growth potential, according to the consistent forecasts of more than 5 institutions, there are 23 innovative drug concept stocks expected to achieve a net profit growth rate of over 20% in 2026 and 2027. In terms of stock price performance, among the aforementioned 23 high-growth potential innovative drug concept stocks, as of the close of January 12th, 9 had retreated more than 20% from their highs since 2025, including Junbo Biotech, Hengrui Medicine, Akeso, MicroPort Biology, and Huayu Pharmaceutical-W.